Astra Favorite: Chilean Group 2 Winner Australia Mia ‘Has Settled In Nicely’ For Michael McCarthy

As the 5-2 morning-line favorite in Saturday's $100,000 Astra Stakes at Santa Anita Park, Australia Mia makes her U.S. bow with high expectations for owner-breeder Don Alberto Stable in the 1 ½-mile turf marathon.

A Kentucky-bred daughter of Street Sense, Australia Mia raced exclusively in Chile before arriving at trainer's Michael McCarthy's Santa Anita barn in October. While in Chile, Australia Mia racked up nine wins in 19 starts, all on turf, including a pair of Group 2's at distances ranging to a mile-and-a-quarter. The 5-year-old mare surfaces in the Astra after working five times at Santa Anita since Dec. 10.

“She's been here quite some time and has settled in nicely with a steady series of works,” McCarthy said Friday morning.

For the Astra, Australia Mia has lured the services of top jockey Frankie Dettori. They will break from post five in a nine-horse field. The Astra will be Australia Mia's first start since last June, a runner-up effort in a Group 3 going a mile and a quarter at Club Hipico.

While a multiple winner at the 10-furlong distance, McCarthy acknowledged the extra quarter mile of the Astra remains a question mark. However, he noted the time was right to get Australia Mia's U.S. campaign started.

“We didn't really find anything that fit on the calendar. We thought a mile might be a little too sharp for her,” McCarthy said. “We'll get started here and if it is a tick too far, we'll cut her back to a mile-and-an-eighth type thing.”

The Astra goes as the eighth race on Saturday's 10 race card with an approximate post time of 3:30.

The field in post position order:

  1. Warrens Candy Girl, Umberto Rispoli, 6-1;
  2. Lady Clementine, Flavien Prat, 5-1;
  3. Queen Ofthe Temple, Juan Hernandez, 3-1;
  4. Duvet Day, Kazushi Kimura, 6-1;
  5. Australia Mia, Frankie Dettori, 5-2;
  6. Almost A Factor, John Velazquez, 15-1;
  7. Tiz An Adventure, Mike Smith, 6-1;
  8. Barrister's Ride, Ricardo Gonzalez, 12-1;
  9. New Heat, Abel Cedillo, 20-1.

The post Astra Favorite: Chilean Group 2 Winner Australia Mia ‘Has Settled In Nicely’ For Michael McCarthy appeared first on Horse Racing News | Paulick Report.

Source of original post

Live Coverage From Fair Grounds This Saturday On FanDuel TV

The Road to the Kentucky Derby runs through Louisiana and FanDuel TV will be live on-site at Fair Grounds as the track hosts a stakes-laden card on Saturday featuring the $200,000 Lecomte Stakes (G3). FanDuel TV's Gabby Gaudet will be providing regular coverage from Fair Grounds throughout the meet with expert analysis, insights and interviews and will be joined by Scott Hazelton this weekend.

The $200,000 Lecomte Stakes, one of six stakes races on the fourteen-race card, has 20-8-6-4-2 Kentucky Derby qualifying points up for grabs for the top five finishers and serves as an early prep race for the $400,000 Risen Star Stakes (G2) on Feb. 18 and the $1 million Louisiana Derby (G2) on March 25. The race has drawn a field of eight Triple Crown hopefuls with Instant Coffee installed as the 5-2 morning line favorite for Brad Cox. A graded stakes winning juvenile, the colt is from the first crop of stallion Bolt d'Oro and will have Luis Saez aboard for his three-year-old debut.

The weekend coverage will continue at Santa Anita with expert selections, interviews and analysis from Todd Schrupp, Simon Bray, Mike Joyce, Christina Blacker, Kurt Hoover and Joaquin Jaime. The featured race is the $100,000 Astra Stakes, a mile and a half turf contest for fillies and mares. The field of nine includes Australia Mia, a homebred for Don Alberto Stable. Trained by Michael McCarthy, the five-year-old mare was a multiple stakes winner in Chile and will be making her North American debut under Frankie Dettori.

At Gulfstream Park, Larry Collmus, Andie Biancone and Matt Bernier will be trackside with coverage of the eleven-race card. The $75,000 Sunshine Turf Stakes headlines the card and has drawn a field of seven including Me and Mr. C, the 2-1 morning line favorite for Mike Maker. The stakes winning gelding was last seen winning an allowance race at Gulfstream in November and will be ridden by Joel Rosario.

In addition to racing from Fair Grounds, Santa Anita and Gulfstream, TV will also be featuring Aqueduct, Laurel Park and more.

The post Live Coverage From Fair Grounds This Saturday On FanDuel TV appeared first on Horse Racing News | Paulick Report.

Source of original post

This Side Up: Lecomte Starts a New Cycle

And so we begin anew. The GIII Lecomte S. always warms the heart: it's like noticing the first buds on the bare trees, as the quiet midwinter promise–familiar, expected, miraculous–of another spring to come.

In trees, each new cycle is nourished by past decay: by roots extending into soil enriched by the leaves discarded at the end of the previous one. And actually it's not dissimilar with selective breeding, so that each generation can recycle its speed, stamina, beauty, bravery.

The world may be a very different place, on and off the track, from the days when Lecomte, the 1850s Louisiana legend honored by this race, was defying the great Lexington in four-mile heats at the old Metairie racecourse in New Orleans. Lecomte, indeed, was both trained and ridden by African Americans who had been purchasable chattels, as you can read in this marvelous story by Kellie Reilly of Brisnet.

 

Listen to Chris McGrath read this edition of This Side Up.

 

But if the demands made of modern racehorses are wildly different, I still find it apt that if you go far enough back in the pedigree of the colt to beat on Saturday, Instant Coffee (Bolt d'Oro), you come to the principal legacy of Lecomte himself.

Louisiana plantation owner Thomas Jefferson Wells had bred Lecomte from a mare named Reel, whose importance to the evolving American breed was only one instance of the transatlantic distaff influence of her exported British sire Glencoe.

Though Lecomte died in a failed adventure to Britain, luckily Wells had first had him cover a handful of mares. One of his daughters was registered, in a fashion that had once been very common, simply as “Lecomte Mare.” Remarkably, she was mated with Lecomte's half-brother by his old rival Lexington. Bear in mind that Lecomte and Lexington were both sons of Boston; that the mare's second dam was by Reel's sire Glencoe; and that her fourth was Reel's mother! Few modern breeders, it is safe to say, would dare to entertain such genetic saturation.

Yet the result of this match, Lizzie G., ties together the ancestry of many great horses. One of her daughters, for instance, produced the iconic Domino; a rather longer line would eventually lead to Affirmed; and, yes, a still more attenuated one brings us to Follow No One (Uncle Mo), the dam of Instant Coffee.

These are clearly all scrolls of parchment, too faded to have the remotest bearing on Instant Coffee's competence for the tasks he could face this spring. But these are the old leaves that nourish the genetic subsoil–and, to me, this little tangent just adds a piquant extra flavor to Instant Coffee happening to line up for the Lecomte.

After all, each of these horses entwine so many different strands: through a trainer or owner or breeding program, for instance, and the things we feel they stand for; or through more peripheral associations, such as the fact that Follow No One was named by Alpine ski racer Lindsey Vonn. She had a commercial partnership with Under Armour, the sportswear company founded by Kevin Plank–whose noble attempt to revive Sagamore Farm as a force on the Turf encompassed Follow No One's racing career. And, now that the mare is on the Upson Downs Farm of Churchill chairman Alex Rankin, there's scope for another colorful thread to be woven into the great Derby tapestry.

And that's just one horse, in one trial. There are 23 futures options entered across five tracks just on Saturday, and so many others to be sieved down over the coming weeks to that final field of 20. Each will have a sentimental cargo of its own, associations that will inspire (or discourage) the allegiance of neutrals.

Down in Louisiana, meanwhile, they can claim a collective stake in the entire Lecomte field, as potential heirs to the 2019 Derby and Preakness winners, the 2021 Derby winner and the 2022 Derby runner-up, who all contested this race, GII Risen Star and GII Louisiana Derby–with the exception of Country House (Lookin At Lucky), who missed this first leg (in order to break his maiden at Gulfstream).

The Fair Grounds rehearsals have been achieving edifying new relevance since their extension in distance. To me, that represents a small but useful redress of the renunciation by modern trainers of the way their predecessors put such a deep foundation of experience and condition into their Classic horses. The old school never minded seeing two-turn horses beaten in sprints, early in the year, because they would gain in fitness and seasoning without ever forcing the engine anywhere near its maximum revs. But now that horses have to tiptoe to Churchill in May, the least they can do is get some mileage. Last year, remember, both Epicenter (Not This Time) and Cyberknife (Gun Runner) were beaten in the Lecomte, but each used that reverse as a springboard to reach the elite of the crop.

There will, no doubt, be other local horses entering the picture. Banishing (Ghostzapper), for instance, will have a spectral presence in the Lecomte, on the clock, after an excursion over the same distance earlier on the card. In breaking his maiden here by eight and a half lengths on Boxing Day, he clocked a marginally faster time than did the winner of the Gun Runner S. With Loggins yet to return to the worktab, it would be heartening if Ghostzapper could reinforce his quest for the Classic success that for now feels like an incongruous omission in the resumé of one of the greats.

The people standing Bolt d'Oro, meanwhile, are similarly not dependent solely on Instant Coffee to maintain his flying start. The champion freshman also has Itzos, half-brother to none other than Rachel Alexandra (Medaglia d'Oro), heading to Turfway after scratching from the Lecomte. He contests a race in which a horse named Rich Strike (Keen Ice) ran a negligible third last year.

So Saturday is only one early step on a long road. Instant Coffee's barnmate Zozos (Munnings) could certainly tell him a thing or two as they're being groomed for their respective races. He chased home Epicenter in the Louisiana Derby last year, before helping to set up the meltdown for Rich Strike at Churchill. But he then disappeared until a stylish resumption last month, and now explores his remaining potential against the thriving Happy American (Runhappy) in the GIII Louisiana S.

The latter represents the same team as Bell's The One (Majesticperfection), brilliantly trained by Neil Pessin to win $2 million before her retirement last fall. She has left a tough void in a barn that mustered no more than 88 starters in 2022, but in this era of “super trainers” with cavalries spread across time zones, a seasoned horseman like Pessin–reliably undiminished in endeavor, skill and passion–still only needs an adequate stone for his sling to cut those Goliaths down to size.

To be fair, that's pretty much what happened in the last Derby. True, I doubt whether a single handicapper would have come up with the right exacta if told by a time traveler, this weekend last year, that they had just seen both the required horses beaten. But we know that the next ones will be out there somewhere, once again; that on those cold stark trees, it's time to look for the first buds.

The post This Side Up: Lecomte Starts a New Cycle appeared first on TDN | Thoroughbred Daily News | Horse Racing News, Results and Video | Thoroughbred Breeding and Auctions.

Source of original post

Ramey: A New Pentosan Drug For Horses Was Just FDA-Approved; What Does It Mean For You?

I thought we'd start off 2023 talking about a product for osteoarthritis in horses, pentosan polysulfate sodium (we'll just call it pentosan from now on). A new, FDA-approved formulation has just been released in the United States, although it's been available in Australia and a few other places since the 1990s.

NOTE: You might have been giving your horse a pentosan product already. There have been compounded formulations of pentosan available for some time in the United States. Compounded drugs are not the same as FDA-approved drugs, although the horse drug market is flooded with compounded products. Compounded medications are the subject of another article, but suffice it to say that if you've been giving pentosan to your horse, depending on where you live, it's production may be more or less regulated, that is, you may be more or less sure that you're getting pentosan in your pentosan. If you want to try the new, FDA-approved product on your horse, you'll have to get it from your veterinarian.

WHAT IS PENTOSAN?

Pentosan is an ester (a chemical term) that's made up of a chain of sugars (known as polysaccharides). In this case, the sugars are called pentoses, that is, they contain five carbon atoms. None of this is particularly important to horse owners (or veterinarians, for that matter), unless you love chemistry, but at least you now know why it's called pentosan (from pentoses).

In its chemical action, pentosan is similar to a class of drugs known as low molecular weight heparins. In people, heparins are used to prevent blood clots, and to treat stroke and heart attacks. In horses, heparin was once tried for treatment of laminitis, but it didn't pan out. This is mostly relevant to you because heparin inhibits blood clotting, and bleeding is a side effect of pentosan (more on that in a bit).

HOW DOES PENTOSAN WORK?

Well, begging questions such as, “If” and “How Well” (more on that in a bit), frankly, it's still a bit of a mystery of pentosan might work for osteoarthritis. Oh sure, there are lots of entirely optimistic proposed mechanism, such as increasing production of hyaluronic acid (which is thought of as a sort of joint lubricant) and increasing production of cartilage components (known as glycosaminoglycans), and maybe it helps prevent enzyme destruction of cartilage, and perhaps it affects the production of cytokines (which are just substances secreted by some cells that have effects on other cells).

Heck, maybe it even sops up free radicals, those dreaded compounds that are said to damage about anything they come in contact with (in the simplistic way of looking at the compounds that seems to be pushed by Dr. Google). But the fact is, nobody really knows how pentosan works for the treatment of osteoarthritis, if in fact it does much at all. To me, this is annoying, because I like to have some idea of how something really works before I give it to a horse. Call me cranky.

WHAT IS PENTOSAN USED FOR?

There is a pentosan pill available for humans. In humans, pentosan may be prescribed to relieve the bladder pain that's caused by a condition known as interstitial cystitis. There, it apparently works by preventing bladder wall irritation. For what it's worth, interstitial cystitis is apparently not a big problem in horses, although it apparently does occur. I've never seen a case.

Of course, the big news in animals – especially insofar as advertising and sponsorship goes – is that it's yet another option for the treatment of osteoarthritis. Interestingly, in humans, pentosan is NOT approved for the treatment of osteoarthritis, in spite of some early evidence which concluded it was helpful (CLICK HERE) which, to me anyway, is curious, because if you want to make a lot of money for a successful treatment for arthritis, there's no better place to start than the human market. That fact is a bit of a red flag for me when it comes to pentosan for osteoarthritis in horses (and dogs, too).

NOTE: Apparently, there are now clinical trials being conducted on pentosan in humans. It will be very interesting to see the results of these trials.

WHAT'S THE CLINICAL EVIDENCE?

While it's been tried in humans – to no avail, apparently, insofar as getting drug approval, and in spite of a couple of studies that showed “promise” – pentosan has been occasionally tested on horses (and dogs, too). For example, it's been reported in an influential book on equine arthritis that a group of racing Thoroughbreds who had chronic osteoarthritis were given pentosan in the muscle once a week for four weeks and that signs of joint disease were “improved” but not eliminated.

In another study, nine horses that got pentosan in an experimental arthritis model had improvement in the quality of their joint cartilage (but we don't know if they got any better – CLICK HERE to see the study). Finally, in another study, a product containing pentosan and a couple of other things didn't do much of anything when administered to horses (CLICK HERE).

Since, sadly, there's not really much robust clinical evidence for the effectiveness of pentosan (after, oh, nearly 30 years), perhaps it might be instructive to ask veterinarians who have been using the stuff what they think. Or, maybe not. I've asked a couple of friends who practice(d) in Australia and one thinks it's wonderful, while the other things it's akin to pouring water on their back. But rather than just rely on two conflicting opinions, in 2014, a survey of 76 Australian veterinarians was published (CLICK HERE) Here's a summary of results

  1. Pentosan was most commonly used as prophylactic therapy prior to competition (80.3%). NOTE: That's right along the lines of the rationale typically used for a bunch of horse products intended to help joints. That is, “We don't know if it will do anything, but it might help.”
  2. Pentosan was considered by 48.2% of respondents to have high efficacy. NOTE: That also means that 51.8% of respondents thought that the product didn't do much, which is right along the opinions of the two people that I asked.
  3. The most common dose regimen for prevention and treatment of OA was 3 mg/kg, intramuscularly, once weekly for four weeks followed by monthly injections. NOTE: That's a combination of the manufacturer's recommendation plus some unknown dosing schedule, which, again, is just like what's used for many other products. First, the products are dosed according to the label, and then, they're given on some other schedule that's often dictated by how much the medication costs. Otherwise stated, you don't really know what you're doing, but at least you're doing something, if you can afford it.
  4. Most respondents (78%) combined PPS with other drugs for treatment of OA. NOTE: That's not much of a ringing endorsement for the effectiveness of the product.
  5. For treating OA, 83% of respondents considered a combination product was more efficacious than pentosan alone. NOTE: This was a curious finding, especially since the research that I previously cited showed exactly the opposite (CLICK HERE).
  6. The most common reason not to use this combination was cost. NOTE: That makes a good deal of sense, actually. It's fine to spend money on your horse but if it doesn't seem to do much, why bother?

SO, WHAT ABOUT THE EVIDENCE THAT GOT THE DRUG APPROVED?

In spite of the previous (underwhelming) evidence, the fact of the matter is that pentosan did get approved by the US Food and Drug Administration, so the evidence had to show something. This is where you have to dig into the evidence a little bit. I did, and here's what I see, based on the drug summary, which you can see if you CLICK HERE.

The manufacturer of the new product did a field study, that is, they were using horses at barns, stables, etc. They ended up with 109 horses that got a shot of pentosan in the muscle once a week for four weeks, and 113 horses that got an injection of saline once a week for the same period (that's according to the recommended dosing regimen).

All of the evaluated horses were lame, and they were graded by the lameness scale developed by the American Association of Equine Practitioners:

  • 0: Lameness not perceptible under any circumstances.
  • 1: Lameness is difficult to observe and is not consistently apparent, regardless of circumstances (e.g., under saddle, circling, inclines, hard surface, etc.).
  • 2: Lameness is difficult to observe at a walk or when trotting in a straight line but consistently apparent under certain circumstances (e.g., weight-carrying, circling, inclines, hard surface, etc.).
  • 3: Lameness is consistently observable at a trot under all circumstances.
  • 4: Lameness is obvious at a walk.
  • 5: Lameness produces minimal weight bearing in motion and/or at rest or a complete inability to move.

So, what were they measuring? The metric for improvement was a change of one level on the AAEP scale. For example, perhaps a horse was lame at the walk initially (grade 4) but after the medication, he was only lame all the time at the trot (grade 3). I guess that's something, but it's not much, in my opinion. In fact, I rarely hear clients congratulate me, saying, “Great doc, after treatment, now he's less bad!” Plus, add that to the fact that the measurement was subjective (“Is he a bit better?”) and the relatively small number of horses (relative to the large trials often conducted in human medicine, that is), and there's some reason to wonder how meaningful the metric really is.

But how about the results? Well, according to the study, 57% of the horses that received pentosan improved. Of course, 36% of the horses that got saline also improved. That's a difference that is statistically significant, that is, it's somewhat less likely (although not impossible) that the results occurred purely by chance.

But there are larger questions that can't really be answered by this study. In fact, you're probably the best person to answer them. Specifically:

  1. Is the relatively modest possibility of mild improvement worth the cost?
  2. Do the results, even if true, really mean anything (that is, are they clinically relevant – I don't think that they're likely to be, but I'm pretty conservative)?
  3. Are the possible side effects worth the risk (more on that, below)?

WHAT ABOUT SIDE EFFECTS?

I'm glad you asked. If you want to give your horse pentosan, there are some side effects you should be aware of. In fact, the study documented several of them, including:

  • Increase in measures of blood clotting (which you'd probably expect in a heparin-like product)
  • Lethargy
  • Behavior changes
  • Colic
  • Stiffness

The effect on blood clotting is real. As a result, I'd probably avoid giving it immediately before your horse is going to do something potentially traumatic (like run, jump, or spin). I'd probably also avoid giving it to a horse that might need surgery. Oh, and, just in case you have blood clotting problems yourself, and since pentosan is an anti-coagulant, if you take an anti-coagulant, you should take care not to inject yourself, or maybe even have someone else do it.

WHAT'S THE BOTTOM LINE?

Frankly, I'm not very impressed. To be fair, I'm pretty conservative, so I'm rarely an early adopter. That said, first of all, this really isn't a new drug – it just finally got approved in the US after being available for nearly 30 years in other countries. Experimental reports – including the one that got the drug improved – aren't particularly robust, that is, you shouldn't expect to see a great improvement, if you see improvement at all. In addition, pentosan is also NOT a pain-relieving medication. The idea that the product might prevent arthritis is mostly just naïve optimism, although, as with other products, and as per the Australian survey, it's probably the number one reason that people will use pentosan.

You'll probably see lots of advertising coming up in the next few months – perhaps you'll even see sponsorships show up at horse shows. Hopefully, I've given you plenty of information with which you can start to make up your own mind.

Dr. David Ramey is a vocal advocate for the application of science to medicine, and—as such—for the welfare of the horse. Thus, he has been a frequent critic of practices that lack good science, such as the diverse therapies collectively known as “alternative” medicine, needless nutritional supplementation, or conventional therapies that lack scientific support.

This article original appeared on Dr. Ramey's website, doctorramey.com and is reprinted here with permission.

The post Ramey: A New Pentosan Drug For Horses Was Just FDA-Approved; What Does It Mean For You? appeared first on Horse Racing News | Paulick Report.

Source of original post

Verified by MonsterInsights